-
-
-
-
-
-
-
Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia
-
-
-
-
-
-
-
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Reata Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – RETA
-
-
-
-
-
-
-
Reata Pharma (RETA) Confirms FDA Advisory Committee Voted No on Efficacy of Bardoxolone
-
-
-
-
-
-
-
Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
-
-
-
-
-
15,631 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

